We are committed to finding a cure for WM.

BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its New Drug Submission (NDS) for BRUKINSA® (zanubrutinib) for the treatment of patients with Waldenström’s… Continue reading

A New Way to Support the WMFC!

Do you know anyone participating in the Scotiabank Toronto Waterfront Marathon?

Did you know that if you sponsor them your donation can go directly to the WMFC?

The Waldenstrom’s Macroglobulinemia Foundation of Canada is an official charity partner of the… Continue reading

1 2 3 18